The pharmacokinetics, pharmacodynamics, safety, and tolerability of single and multiple intravenous upacicalcet, a new renally excreted calcimimetic agent, were evaluated in patients with secondary hyperparathyroidism undergoing hemodialysis.

Upacicalcet persisted in a dose-dependent manner until the time of the next dialysis, was well removed by dialysis, and constant blood concentrations were maintained when the same doses were administered repeatedly.

Pharmacodynamic parameters, such as serum intact parathyroid hormone and calcium levels, also changed according to the plasma upacicalcet concentration.

No severe concerns about the safety and tolerability of upacicalcet were observed.